Gastrointestinal Cancer News

Phase 3 studies of pembrolizumab — with chemotherapy for metastatic castration-resistant prostate cancer and with lenvatinib for unresectable liver cancer — did not meet primary endpoints of survival, according to the agent’s manufacturer.

Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.

In this episode, host Shikha Jain, MD, speaks with Helio Genomics’ Justin Chen Li about the ways in which AI has been incorporated into oncologic care, how this technology can improve care disparities, and more.

For patients with unresectable colorectal cancer liver metastases and right-sided RAS or BRAF mutations, FOLFOXIRI plus bevacizumab vs. FOLFOX/FOLFIRI plus bevacizumab significantly increased PFS, according toASCO Annual Meeting results.

Transcatheter arterial chemoembolization alone and with microwave ablation yielded comparable overall survival rates in patients with recurrent small hepatocellular carcinoma after resection, per research in BMC Gastroenterology.

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the IMPROVE trial, which she said showed significant results in terms of the length of PFS on treatment with an intermittent panitumumab plus FOLFIRI strategy.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.

Black and Hispanic patients with advanced hepatocellular carcinoma had a lower likelihood than their white counterparts of receiving immunotherapy, which appeared more effective than chemotherapy for the disease, according to study results.

Most gastrointestinal tract surgeries performed before hospice admission were for urgent or emergent complications of cancer and required patient hospitalization in the preceding 3 years, according to a California-based cohort study.